Profil
Damon C.
Smith is the founder of TALLC Corp., Inc. He worked as a Senior Vice President of Research & Development at Labopharm, Inc., a Development Director at Therapeutics Antibodies, Inc., a Research Director at ConjuChem, Inc., and an Executive Director of Development at Protherics Plc.
Dr. Smith received his undergraduate and doctorate degrees from the University of Essex.
Aktive Positionen von Damon C. Smith
| Unternehmen | Position | Beginn |
|---|---|---|
TALLC Corp., Inc.
 TALLC Corp., Inc. Pharmaceuticals: MajorHealth Technology TALLC Corp, Inc. operates as a pre-clinical stage pharmaceutical company. It focuses on the development of TA-A001, a novel endocannabinoid CB2 receptor activator with potent anti-inflammatory analgesic properties. The company was founded by Damon Smith, Melanie Kelly and Guy Chamberland and is headquartered in Laval, Canada. | Gründer | - |
Ehemalige bekannte Positionen von Damon C. Smith
| Unternehmen | Position | Ende |
|---|---|---|
| Therapeutics Antibodies, Inc. | Corporate Officer/Principal | - |
ConjuChem, Inc.
 ConjuChem, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem, Inc. is a biotechnology company that has developed the Drug Affinity Complex (DAC™) Technology, a platform enabling the rapid creation of improved, patentable drugs from existing small organic compounds or peptides. | Technik-/Wissenschafts-/F&E-Leiter | - |
Protherics Plc
 Protherics Plc Pharmaceuticals: MajorHealth Technology Protherics Plc researches, develops, and manufactures biopharmaceutical products. It provides critical care and cancer related products. Its products include CroFab, DigiFab, and ViperaTAb. It has offices in the United Kingdom, the United States, and Australia. The company was founded in 1987 and is headquartered in London, UK. | Corporate Officer/Principal | - |
Labopharm, Inc.
 Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Damon C. Smith
| University of Essex | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Protherics Plc
Protherics Plc Pharmaceuticals: MajorHealth Technology Protherics Plc researches, develops, and manufactures biopharmaceutical products. It provides critical care and cancer related products. Its products include CroFab, DigiFab, and ViperaTAb. It has offices in the United Kingdom, the United States, and Australia. The company was founded in 1987 and is headquartered in London, UK. | Health Technology |
ConjuChem, Inc.
ConjuChem, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem, Inc. is a biotechnology company that has developed the Drug Affinity Complex (DAC™) Technology, a platform enabling the rapid creation of improved, patentable drugs from existing small organic compounds or peptides. | Health Technology |
Labopharm, Inc.
Labopharm, Inc. BiotechnologyHealth Technology Labopharm, Inc. discovers and develops drugs. The company was founded in 1990 and is headquartered in Montreal, Canada. | Health Technology |
| Therapeutics Antibodies, Inc. | |
TALLC Corp., Inc.
TALLC Corp., Inc. Pharmaceuticals: MajorHealth Technology TALLC Corp, Inc. operates as a pre-clinical stage pharmaceutical company. It focuses on the development of TA-A001, a novel endocannabinoid CB2 receptor activator with potent anti-inflammatory analgesic properties. The company was founded by Damon Smith, Melanie Kelly and Guy Chamberland and is headquartered in Laval, Canada. | Health Technology |